The Ultimate Fighting Championship (UFC) drug testing program is a serious matter, even for fighters who haven't stepped into the Octagon in years. A recent discovery has raised eyebrows in the MMA community. In 2025, a drug test was administered to Sheldon Westcott, a Canadian fighter who hasn't competed since 2016. This revelation has sparked curiosity and raised questions about the purpose of such testing.
Sheldon Westcott, now 41, gained recognition through his participation in The Ultimate Fighter: Nations in 2014. Although he lost the final match to Elias Theodorou, his performance earned him additional UFC appearances. Westcott's record shows a 1-1 outcome in his next two Octagon appearances, followed by a withdrawal from a fight in December 2017, after which he disappeared from the scene.
The question arises: why is the UFC's drug-testing agency still monitoring Westcott? It's highly unlikely that Westcott is planning a comeback at 41. The promotion's efforts in testing a non-competing fighter seem unnecessary and raise concerns about the efficiency of their drug-testing program.
This incident highlights the importance of reevaluating and optimizing the UFC's drug-testing procedures to ensure fairness and focus on active competitors. The community eagerly awaits further clarification on this matter, emphasizing the need for transparency and accountability in the organization's operations.
